Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (1533)	4/10/1998 10:44:00 PM
From: Bob L	Read Replies (1) \| Respond to of 1762

It's too bad even in this age that patients aren't really in control of their own destinies, What I find fascinating is how much the opinion of Rituxan has changed in the last 6 months among doctors treating my dad. It has gone from "not worth trying" or "not nearly as promising as Bexxar", to "might try it" a couple of months ago, to "definitely worth considering" as of earlier today. (In the context of a possible next step after the almost inevitable reoccurrence that lies down the road even after Bexxar treatment.) Two things seem to contribute to this. 1) Rituxan is now approved and actively marketed. This seems to have at least a psychological effect on opinions of it. 2) These particular doctors have treated a few more patients with it, including those who have failed or relapsed after Bexxar, and have seen some positive results. So, like most people, doctors seem to be more comfortable with things they have first-hand positive experience with or things that are becoming generally accepted as effective. And opinions are changing as new information comes in. Not a profound discovery, I know, but there it is.